Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Item
http://www.wikidata.org/entity/Q35828688
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityThe percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencingQuantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma.NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.Tumour heterogeneity: principles and practical consequences.Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.
P2860

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Item
http://www.wikidata.org/entity/Q35828688
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@ast
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@en
type
label
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@ast
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@en
prefLabel
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@ast
Molecular heterogeneity assess ...... advanced lung adenocarcinoma.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Molecular heterogeneity assess ...... t advanced lung adenocarcinoma
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932